Toxic Injury to the Gastrointestinal Tract After Ipilimumab Therapy for Advanced Melanoma

Benjamin Shepard, DO; Carrie Trower, PA; and Scott Hendrickson, DO
Notes and Affiliations
Notes and Affiliations

Received: July 8, 2017

Accepted: August 9, 2017

Published: January 1, 2018

From the Department of Gastroenterology at the Oklahoma State University Medical Center (Dr Shepard) and the Departments of Gastroenterology (Drs Shepard and Hendrickson) and Pathology (Ms Trower) at the Southwestern Regional Medical Center in Tulsa, Oklahoma.

J Osteopath Med; 118(1): 40-44

Ipilimumab, cytotoxic T-lymphocyte-associated protein 4–blocking antibody, is known to precipitate tissue-specific immune-related adverse events. The second most common site for immune-related adverse events is the gastrointestinal tract, with toxic injury resulting in diarrhea, colitis, and enterocolitis. In the present case, a woman who received ipilimumab 2 weeks prior was found to have severe, diffuse corticosteroid-refractory gastrointestinal tract toxic injury affecting the stomach, small bowel, and colon.

Read Full Article